Oklahoma Medical Research Foundation

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Oklahoma Medical Research Foundation sits in the top decile of US sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count).

12 total trials 1 currently recruiting 9 completed early-phase tilt top decile by trial count

Oklahoma Medical Research Foundation: 12 sponsored US clinical trials, 1 recruiting.

Oklahoma Medical Research Foundation sponsors 12 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting, and 9 completed. 2 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Systemic Lupus Erythematosus, with 3 trials.

Top-decile sponsor footprint

Oklahoma Medical Research Foundation ranks in the top decile of sponsors by registered trial count (#1,137 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

F 44/100

9 of 11 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (81.8%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

12 total, page 1 of 1

RECRUITING NA

Skeletal Muscle Aging and Responsiveness in Aged People With MS

NCT07500727
COMPLETED Phase 3

Antecedent Metabolic Health and Metformin Aging Study

NCT04264897
TERMINATED Phase 2

MRI Evaluation Assessing Synovitis to Address the Unmet Need for Reliable Endpoints in SLE

NCT03355482
COMPLETED Phase 2

Clarification of Abatacept Effects in SLE With Integrated Biologic and Clinical Approaches

NCT02270957
TERMINATED NA

Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)

NCT01781611
COMPLETED Phase 1

Safety of Zostavax Vaccination in Rheumatoid Arthritis

NCT01506661
COMPLETED Phase 1

Zostavax in Systemic Lupus Erythematosus

NCT01474720
COMPLETED Phase 3

The Effect of Certolizumab Pegol on MRI Synovitis and Bone Edema in Rheumatoid Arthritis Patients

NCT01213017
COMPLETED Phase 1

Biomarkers of Lupus Disease: Serial Biomarker Sampling in Patients With Active Systemic Lupus Erythematosus (SLE)

NCT00987831
COMPLETED Phase 1

Biomarker-Linked Outcomes of Cellcept in Lupus Arthritis

NCT00594932
COMPLETED

Genetic Study of Lupus Patients and Their Families

NCT00235378
COMPLETED

Lupus Genetics Studies

NCT00071175

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 2
Phase 3 2

Therapeutic Areas

Systemic Lupus Erythematosus 3
Arthritis 1

What is open in the Oklahoma Medical Research Foundation pipeline

1 recruiting of 12 indexed (8% open); 9 completed (75%).

Phase mix: 2 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Systemic Lupus Erythematosus (3 trials), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Oklahoma Medical Research Foundation: open-pipeline peers nationwide

Peers matched on 12 registered trials and 8% open enrollment, not the therapeutic-area sidebar.

Oklahoma Medical Research Foundation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 10152025 0%5%10%15%20% Total trials Recruiting share Oklahoma Medical Research FoundationAlachua Government ServicesAllergy TherapeuticsAmpio Pharmaceuticals.AngiodynamicsAcrotech BiopharmaAtlanta VA Medical CenterBeacon TherapeuticsBoston VA Research Institute
Oklahoma Medical Research Foundation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Oklahoma Medical Research Foundation sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 12 trials (± recruiting share)

Sponsors near 8% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Oklahoma Medical Research Foundation page

12 registered trials is a research-attention snapshot, not an endorsement of Oklahoma Medical Research Foundation or any single study.

  • 1 of Oklahoma Medical Research Foundation's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Systemic Lupus Erythematosus is the condition Oklahoma Medical Research Foundation studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Systemic Lupus Erythematosus trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Oklahoma Medical Research Foundation pipeline card: 12 registered trials from official public datasets.Report a data error.